IPO of venture-backed ProNAi Therapeutics pulls in $158.4 mln in close
ProNAi Therapeutics Inc has completed its previously-announced initial public offering of common shares on the NASDAQ Global Market. The company, which began trading under the symbol "DNAI" on July 16, raised a total of US$158.4 million in gross proceeds, including shares sold through the underwriters' over-allotment option. Headquartered in Vancouver, ProNAi is developing and commercializing a new class of therapies through its DNA interference platform for patients with cancer and hematological diseases. It is backed by mostly U.S. venture capital firms, including Vivo Capital, Frazier Healthcare Ventures and OrbiMed Advisors.
24 July 2015•2 mins read
